vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Orange County Bancorp, Inc. (OBT). Click either name above to swap in a different company.
Orange County Bancorp, Inc. is the larger business by last-quarter revenue ($33.0M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -0.8%, a 38.5% gap on every dollar of revenue. On growth, Orange County Bancorp, Inc. posted the faster year-over-year revenue change (20.6% vs -25.7%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-15.8M). Over the past eight quarters, Orange County Bancorp, Inc.'s revenue compounded faster (14.3% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.
CTMX vs OBT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $33.0M |
| Net Profit | $-154.0K | $12.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 41.4% |
| Net Margin | -0.8% | 37.6% |
| Revenue YoY | -25.7% | 20.6% |
| Net Profit YoY | 97.6% | 73.5% |
| EPS (diluted) | — | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $33.0M | ||
| Q3 25 | — | $33.7M | ||
| Q2 25 | $18.7M | $32.5M | ||
| Q1 25 | $50.9M | $28.0M | ||
| Q4 24 | $38.1M | $27.4M | ||
| Q3 24 | $33.4M | $27.1M | ||
| Q2 24 | $25.1M | $27.9M | ||
| Q1 24 | $41.5M | $25.3M |
| Q4 25 | — | $12.4M | ||
| Q3 25 | — | $10.0M | ||
| Q2 25 | $-154.0K | $10.5M | ||
| Q1 25 | $23.5M | $8.7M | ||
| Q4 24 | $18.9M | $7.2M | ||
| Q3 24 | $5.7M | $3.2M | ||
| Q2 24 | $-6.5M | $8.2M | ||
| Q1 24 | $13.8M | $9.3M |
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | 38.6% | ||
| Q2 25 | -6.9% | 41.9% | ||
| Q1 25 | 44.4% | 40.3% | ||
| Q4 24 | 46.4% | 32.8% | ||
| Q3 24 | 12.3% | 14.8% | ||
| Q2 24 | -33.7% | 36.6% | ||
| Q1 24 | 28.1% | 45.9% |
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | -0.8% | 32.2% | ||
| Q1 25 | 46.2% | 31.1% | ||
| Q4 24 | 49.6% | 26.2% | ||
| Q3 24 | 17.2% | 11.8% | ||
| Q2 24 | -26.0% | 29.4% | ||
| Q1 24 | 33.3% | 36.7% |
| Q4 25 | — | $0.94 | ||
| Q3 25 | — | $0.75 | ||
| Q2 25 | — | $0.87 | ||
| Q1 25 | — | $0.77 | ||
| Q4 24 | — | $0.64 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.73 | ||
| Q1 24 | — | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $284.4M |
| Total Assets | $175.1M | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $284.4M | ||
| Q3 25 | — | $270.1M | ||
| Q2 25 | $119.9M | $252.6M | ||
| Q1 25 | $25.0M | $201.3M | ||
| Q4 24 | $-456.0K | $185.5M | ||
| Q3 24 | $-23.5M | $193.1M | ||
| Q2 24 | $-31.2M | $177.5M | ||
| Q1 24 | $-31.7M | $168.7M |
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $175.1M | $2.6B | ||
| Q1 25 | $98.5M | $2.6B | ||
| Q4 24 | $120.5M | $2.5B | ||
| Q3 24 | $139.0M | $2.5B | ||
| Q2 24 | $159.2M | $2.5B | ||
| Q1 24 | $184.7M | $2.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $43.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $41.3M |
| FCF MarginFCF / Revenue | -84.6% | 125.1% |
| Capex IntensityCapex / Revenue | 0.1% | 7.6% |
| Cash ConversionOCF / Net Profit | — | 3.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $69.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $43.8M | ||
| Q3 25 | — | $30.2M | ||
| Q2 25 | $-15.8M | $-5.0M | ||
| Q1 25 | $-21.0M | $4.8M | ||
| Q4 24 | $-19.9M | $34.6M | ||
| Q3 24 | $-20.7M | $10.2M | ||
| Q2 24 | $-19.5M | $9.3M | ||
| Q1 24 | $-26.0M | $2.3M |
| Q4 25 | — | $41.3M | ||
| Q3 25 | — | $29.6M | ||
| Q2 25 | $-15.8M | $-5.7M | ||
| Q1 25 | $-21.2M | $4.3M | ||
| Q4 24 | $-20.0M | $32.9M | ||
| Q3 24 | $-20.7M | $10.0M | ||
| Q2 24 | $-19.6M | $9.2M | ||
| Q1 24 | $-26.2M | $2.0M |
| Q4 25 | — | 125.1% | ||
| Q3 25 | — | 87.8% | ||
| Q2 25 | -84.6% | -17.5% | ||
| Q1 25 | -41.6% | 15.5% | ||
| Q4 24 | -52.5% | 120.0% | ||
| Q3 24 | -62.1% | 36.7% | ||
| Q2 24 | -78.2% | 32.8% | ||
| Q1 24 | -63.1% | 7.9% |
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | 0.1% | 2.3% | ||
| Q1 25 | 0.2% | 1.8% | ||
| Q4 24 | 0.2% | 6.3% | ||
| Q3 24 | 0.1% | 1.1% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 0.3% | 1.0% |
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.01× | ||
| Q2 25 | — | -0.47× | ||
| Q1 25 | -0.89× | 0.56× | ||
| Q4 24 | -1.05× | 4.83× | ||
| Q3 24 | -3.61× | 3.19× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | -1.89× | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
OBT
Segment breakdown not available.
